An “expression of concern” (EOC) is a formal notice issued by a scientific journal signaling unresolved questions about a published study’s data integrity, methodology, or ethical compliance. The journal Anticancer Research issued an EOC for Hulscher et al. (2026) on June 1, 2026, citing concerns about data verifiability, statistical reliability, and ethical oversight.
Extended Answer
When a peer-reviewed journal publishes an expression of concern, it is not a retraction — but it is a serious, formal warning to the scientific community and the public that something about a study warrants scrutiny before its findings are accepted or acted upon.
What an expression of concern (EOC) typically signals:
- Data verifiability problems: Questions exist about whether patient data was collected as described or is accessible for audit
- Statistical reliability questions: Reported outcomes may not hold up under independent analysis, or methodology may make the statistics uninterpretable
- Ethical oversight gaps: The study may lack documented Institutional Review Board (IRB) approval or adequate informed consent procedures — foundational requirements for human research
Why the Hulscher 2026 EOC carries particular weight:
- The study enrolled 197 cancer patients using an off-label compounded ivermectin-mebendazole product sold exclusively by The Wellness Company (TWC)
- All 12 listed authors are affiliated with and/or compensated by TWC and/or the McCullough Foundation — a conflict-of-interest concentration that is highly unusual in clinical research
- The 84.4% “clinical benefit” figure is based entirely on self-reported outcomes in an observational design, without a control group, placebo, or blinding — meaning it cannot demonstrate that the treatment caused any benefit
- Understanding why observational and self-reported data have serious limits compared to randomized clinical trials is essential for interpreting why self-reported benefit rates alone cannot establish treatment efficacy
EOC vs. retraction — what’s the difference?
An EOC means the journal has flagged concerns but has not yet concluded the study must be removed. The study remains published but under a cloud of formal doubt. Readers — including clinicians and patients — are formally advised to interpret findings with caution.
This study is entirely separate from:
- The National Cancer Institute’s independent preclinical laboratory research exploring ivermectin’s biological mechanisms in cancer cells
- The registered human clinical trial NCT05318469, studying ivermectin alongside checkpoint inhibitors in metastatic triple-negative breast cancer — a rigorously designed trial whose current status and enrollment should be verified at ClinicalTrials.gov
For cancer patients and caregivers, understanding how to evaluate cancer treatment claims is an essential skill when viral claims circulate online.
Related Questions
Q: Does an expression of concern mean the Hulscher 2026 ivermectin study is fraudulent?
Not necessarily. An EOC means unresolved concerns exist — not that fraud is proven. It signals that independent verification has not been possible and that conclusions should not be clinically applied. For a deeper look at what this specific study’s evidence actually shows, a critical analysis of what patients need to know about the 2026 ivermectin cancer study examines the findings in detail.
Q: Is ivermectin approved or recommended as a cancer treatment?
No. As of 2026, ivermectin has no FDA approval or established guideline recommendation for any cancer indication. Preclinical laboratory findings exist, but they have not translated into proven clinical benefit in controlled human trials. For a deeper look at what the research actually shows, what the science says about ivermectin as a cancer treatment provides important context for separating laboratory findings from clinical evidence.
Q: What is The Wellness Company’s role in the Hulscher 2026 study, and why does it matter?
TWC is the sole commercial seller of the specific compounded ivermectin-mebendazole product studied. When a commercial entity with direct financial interest in a product’s adoption is also the sole funder and employer of all study authors, this represents a conflict of interest that independent scientific standards require to be disclosed, scrutinized, and weighed heavily by readers. Asking your oncologist targeted questions about alternative cancer therapies can help you navigate these complex research landscapes with professional guidance.
About Sood Laboratory as an Educational Resource
Sood Laboratory (ASL) is committed to helping cancer patients and caregivers navigate an increasingly complex information environment — including viral claims about unproven treatments. ASL’s educational content does not constitute medical advice, but it is designed to help you ask better questions of your oncology team and evaluate research critically before making any treatment decisions. Visit ASL to explore evidence-informed cancer education resources built for patients who want to understand the science behind the headlines.
Additional Related Articles
📖 How to Identify Conflicts of Interest in Cancer Research — Explains what author financial disclosures mean and how commercial funding relationships affect how you should weigh study conclusions.
📖 What the NCI’s Preclinical Ivermectin Research Actually Shows — and What It Doesn’t — Distinguishes laboratory findings from clinical evidence, and explains why promising lab results frequently do not translate to human benefit.
📖 Understanding Clinical Trial Design: Why Observational Studies Cannot Prove a Treatment Works